Sustained-release bupropion versus naltrexone in the treatment of pathological gambling: A preliminary blind-rater study

Journal of Clinical Psychopharmacology

Volumn 25, Issue 6, 2005, Pages 593-596

  Dannon, Pinhas N ^a,b   Lowengrub, Katherine ^a   Musin, Ernest ^a   Gonopolski, Yehudit ^a   Kotler, Moshe ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b Rehovot Community Mental Health and Rehabilitation Clinic   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; NALTREXONE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; AGITATION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANXIETY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BEHAVIOR; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DEPRESSION; DIZZINESS; DRUG EFFICACY; FREQUENCY ANALYSIS; GASTROINTESTINAL DISEASE; HAMILTON SCALE; HUMAN; INSOMNIA; INTERVIEW; MALE; MONEY; NAUSEA; NERVOUSNESS; ORTHOSTATIC HYPOTENSION; PATHOLOGICAL GAMBLING; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SELF REPORT; SIDE EFFECT; SLEEP DISORDER; SUSTAINED DRUG RELEASE; SUSTAINED RELEASE FORMULATION; SYMPTOM; TIME SERIES ANALYSIS; TREATMENT OUTCOME; VERTIGO; VOMITING; XEROSTOMIA;

ADULT; BUPROPION; COHORT STUDIES; DELAYED-ACTION PREPARATIONS; DOPAMINE UPTAKE INHIBITORS; GAMBLING; HUMANS; MALE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; PILOT PROJECTS; SINGLE-BLIND METHOD; SOCIOECONOMIC FACTORS; TREATMENT OUTCOME;

EID: 27944462660     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000186867.90289.ed     Document Type: Article

References (26)

1. World Health Organization. The ICD-10 Classification of Mental and Behavioral Disorders. Geneva, Switzerland: World Health Organization; 1992.
2. Shaffer HJ, Hall MN, Vander Bilt J. Estimating the prevalence of disorder gambling behavior in the United States and Canada: a research synthesis. Am J Public Health. 1999;89:1369-1376.
3. Hollander E, Buchalter AJ, DeCaria CM. Pathological gambling. Psychiatr Clin North Am. September 2000;23(3):629-642.
4. Grant JE, Kim SW, Potenza MN. Advances in the pharmacological treatment of pathological gambling. J Gambl Stud. Spring 2003;19(1):85-109.
5. Volpicelli JR, Alterman AI, Hayashida M, et al. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry. November 1992;49(11):876-880.
6. Hollister LE, Schwin RL, Kasper P. Naltrexone treatment of opiate-dependent persons. Drug Alcohol Depend. May 1977;2(3):203-209.
7. Grant JE, Kim SW. An open-label study of naltrexone in the treatment of kleptomania. J Clin Psychiatry. April 2002;63(4):349-356.
8. Kim SW, Grant JE. An open naltrexone treatment study in pathological gambling disorder. Int Clin Psychopharmacol. September 2001;16(5):285-289.
9. Kim SW, Grant JE, Adson DE, et al. Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biol Psychiatry. June 1, 2001;49(11):914-921.
10. Belson MG, Kelly TR. Bupropion exposures: clinical manifestations and medical outcome. Emerg Med. 2002;23:223-230.
11. Levin FR, Evans SM, McDowell DM, et al. Bupropion treatment for cocaine abuse and adult attention-deficit/hyperactivity disorder. J Addict Dis. 2002;21(2):1-16.
12. Tardieu S, Poirier Y, Micallef J, et al. Amphetamine-like stimulant cessation in an abusing patient treated with bupropion. Acta Psychiatr Scand. January 2004;109(1):75-77; [discussion 77-78].
13. Chan-Ob T, Kuntawongse N, Boonyanaruthee V. Bupropion for amphetamine withdrawal syndrome. J Med Assoc Thai. December 2001;84(12):1763-1765.
14. Sullivan MA, Covley CL. Nicotine dependence: the role for anti-depressants and anxiolytics. Curr Opin Investig Drugs. 2002;3:262-271.
15. Black D. An open-label trial of bupropion in the treatment of pathological gambling. J Clin Psychopharmacol. 2004;24(1):108-109.
16. Dannon PN. Preliminary findings on the use of buproprion for pathological gambling. Paper presented at: American Psychiatric Association Annual Meeting (157th) New Research Poster Presentation, May 21, 2004; New York.
17. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50-55.
18. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. February 1960;23:56-62.
19. Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville, Md: US Department of Health, Education, and Welfare Publication (ADM); 1976:76-338.
20. Lesieur H, Blume SB. The South Oaks Gambling Screen (the SOGS): a new instrument for the identification of pathological gamblers. Am J Psychiatry. 1987;144:1184-1188.
21. Grant JE, Kim SW, Potenza MN, et al. Paroxetine treatment of pathological gambling: a multi-centre randomized controlled trial. Int Clin Psychopharmacol. July 2003;18(4):243-249.
22. Sood ED, Pallanti S, Hollander E. Diagnosis and treatment of pathologic gambling. Curr Psychiatry Rep. May 2003;5(1):9-15.
23. Gelenberg A, Bassuk EL. The Practitioner's Guide to Psychoactive Drugs. 4th ed. New York: Plenum Medical Book Co; 1997.
24. Bechara A. Risky business: emotion, decision-making, and addiction. J Gambl Stud. Spring 2003;19(1):23-51.
25. Volpicelli JR. Alcohol abuse and alcoholism: an overview. J Clin Psychiatry. 2001;62(20):4-10.
26. Zwar N, Richmond R. Buproprion sustained release: a therapeutic review of Zyban. Aust Fam Physician. 2002;31:443-447.